Spots Global Cancer Trial Database for Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients
Official Title: Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients
Study ID: NCT01718613
Conditions
Study Description
Brief Summary: Although arginine vasopressin has been used as an additional drug in refractory shock in worldwide clinical practice, there are no prospective studies using it as a first choice therapy in patients with cancer and septic shock. The aim of this study is assess if the use of arginine vasopressin would be more effective on treatment of septic shock in cancer patients than norepinephrine, decreasing the composite end point of mortality and organ failure in 28 days.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Sao Paulo/SP, Brazil
Contact Details
Name: Cristiane M Zambolim, MD
Affiliation: Department of Anesthesia and Critical Care, Intensive Care Unit - ICESP
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
